Ralliant Corporation (NYSE:RAL) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Ralliant has a consensus analyst rating of “Moderate Buy” from 12 firms (1 sell, 4 holds, 7 buys) with an average 12‑month price target of $50.50, although several brokers recently trimmed their targets.
• Insiders bought 8,145 shares (~$332k) in the past three months (including SVP Amir Kazmi and Director Kate Mitchell), while major institutions like Vanguard and other funds materially increased stakes, indicating growing investor confidence.
• Ralliant beat estimates in the latest quarter—EPS $0.69 vs $0.67 and revenue $554.6M vs $543.0M—and issued Q1 2026 EPS guidance of 0.460–0.520 and FY 2026 guidance of 2.220–2.420; the stock trades in the mid‑$40s with a market cap near $5.11B.

Ralliant Corporation (NYSE:RAL - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twelve research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $50.50.

Several equities analysts have weighed in on the stock. Citigroup lowered their price target on shares of Ralliant from $61.00 to $51.00 and set a "buy" rating on the stock in a report on Friday, February 6th. Vertical Research upgraded shares of Ralliant from a "hold" rating to a "buy" rating and set a $45.00 price objective on the stock in a research report on Friday, February 6th. Royal Bank Of Canada lowered their target price on shares of Ralliant from $52.00 to $41.00 and set a "sector perform" rating on the stock in a research note on Friday, February 6th. Morgan Stanley reaffirmed an "overweight" rating and issued a $45.00 target price on shares of Ralliant in a report on Friday, February 6th. Finally, Truist Financial cut their price target on Ralliant from $62.00 to $49.00 and set a "buy" rating for the company in a research note on Friday, February 6th.

Insider Activity

In other Ralliant news, SVP Amir A. Kazmi bought 2,545 shares of the firm's stock in a transaction that occurred on Friday, February 6th. The shares were bought at an average price of $39.27 per share, with a total value of $99,942.15. Following the purchase, the senior vice president owned 39,699 shares of the company's stock, valued at $1,558,979.73. This trade represents a 6.85% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Kate Mitchell purchased 2,350 shares of the stock in a transaction that occurred on Tuesday, February 10th. The stock was acquired at an average cost of $42.48 per share, for a total transaction of $99,828.00. Following the completion of the acquisition, the director owned 8,411 shares in the company, valued at $357,299.28. This represents a 38.77% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 8,145 shares of company stock valued at $332,233 in the last three months.

Hedge Funds Weigh In On Ralliant

Hedge funds have recently modified their holdings of the stock. Phocas Financial Corp. lifted its position in shares of Ralliant by 81.2% in the fourth quarter. Phocas Financial Corp. now owns 157,116 shares of the company's stock worth $7,999,000 after buying an additional 70,403 shares in the last quarter. Vanguard Group Inc. increased its stake in Ralliant by 10.7% in the 3rd quarter. Vanguard Group Inc. now owns 14,589,423 shares of the company's stock worth $637,995,000 after acquiring an additional 1,415,327 shares during the last quarter. Welch & Forbes LLC bought a new stake in Ralliant in the 3rd quarter worth approximately $854,000. SG Capital Management LLC bought a new stake in Ralliant in the third quarter worth $8,139,000. Finally, Allspring Global Investments Holdings LLC raised its stake in Ralliant by 5,269.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 317,038 shares of the company's stock valued at $14,000,000 after purchasing an additional 311,134 shares in the last quarter.

Ralliant Stock Performance

Shares of RAL opened at $45.71 on Thursday. The business has a 50-day simple moving average of $43.49 and a two-hundred day simple moving average of $46.75. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.38. Ralliant has a 52 week low of $37.27 and a 52 week high of $57.02. The stock has a market cap of $5.11 billion and a price-to-earnings ratio of 23.32.

Ralliant (NYSE:RAL - Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.02. The company had revenue of $554.60 million for the quarter, compared to analysts' expectations of $543.04 million. The firm's quarterly revenue was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 23rd. Stockholders of record on Monday, March 9th were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, March 9th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. Ralliant's dividend payout ratio is 10.20%.

Ralliant Company Profile

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.